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Introduction
The human bone marrow contains a distinct stromal cell 
fraction  referred  to  as  multipotent  mesenchymal  stem 
(stromal) cells or MSCs [1]. Although the stromal fraction 
of bone marrow was originally considered to be merely a 
structural  supportive  framework  for  the  hemato  poietic 
system, numerous studies have now shown that MSCs can 
give  rise  to  a  wide  array  of  mesenchymal  cell  types, 
including  bone,  fat,  and  cartilage  [1].  Since  the  first 
published  report  by  Friedenstein  and  colleagues  [2] 
describing the expansion of an adherent, spindle-shaped 
population of cells from whole human bone marrow, MSC 
or MSC-like cells have also been expanded from numerous 
other  compartments,  including  skeletal  muscle,  adipose 
tissue,  umbilical  cord,  synovium,  dental  pulp,  amniotic 
fluid, human embryonic stem cells, and numerous other 
sources [3,4]. Although much focus has been placed on the 
use of MSCs for cell-based therapies [5], more recently, a 
great deal of attention has been given to the use of MSCs 
for paracrine support and immune modulation, including 
the prevention of graft-versus-host disease [6-8].
As it has been estimated that human MSCs comprise a 
mere 0.001 to 0.01% of total bone marrow mononuclear 
cells [9], this population requires extensive in vitro cell-
culture expansion to obtain sufficient numbers for basic 
biologic or clinical applications. Historically, MSC culture 
medium  has  comprised  a  basal  culture  medium  (i.e. 
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Essential Medium alpha) supplemented with fetal bovine 
serum (FBS) with or without additional growth factors 
(i.e.  bFGF).  Although  these  traditional  formulations 
provide robust undifferentiated MSC expansion, the ill-
defined  nature  of  FBS  is  undesirable  for  downstream 
research  and  therapeutic  applications  and  provides  in-
con  sistent  lot-to-lot  performance.  To  overcome  the 
inconsistent performance associated with FBS, commer-
cial  vendors  and  researchers  alike  have  implemented 
quality-control measures in which individual lots of FBS 
are  prescreened  for  performance,  a  costly  and  time-
consuming activity. In addition, the variability associated 
with FBS results in an overall inconsistent reagent and 
thereby  introduces  variability  between  experimental 
results, making data comparisons (i.e. cellular differen-
tiation,  genomics,  and  proteomics)  more  difficult.  To 
circumvent this issue, a robust serum-free MSC culture 
medium has become absolutely necessary. We describe 
here a more-defined, serum-free MSC culture medium 
that can support the robust expansion of undifferentiated 
human  MSCs.  Characterization  of  this  serum-free 
expanded MSC population reveals a similar phenotype 
and expression profile compared with cells expanded in 
traditional serum-containing medium, while maintaining 
the defining growth and differentiation characteristics of 
human MSCs. In addition, it is revealed that PDGF-BB, 
bFGF,  and  TGF-β1,  three  growth  factors  we  have  pre-
viously  shown  to  support  the  expansion  of  undiffer-
entiated human MSCs [10], support human MSC expan-
sion in a synergistic manner in this serum-free formu-
lation. Although the described serum-free MSC culture 
medium is not free of xenogeneic components, this work 
sets  the  stage  for  serum-free  MSC  cell  culture  and 
thereby provides a necessary research tool for the basic 
biologic understanding of human MSCs cultured under 
serum-free conditions.
Materials and methods
Human bone marrow MSC donor pool generation
To generate a passage 4, four-donor pool, human MSCs 
were obtained from two sources: (a) cryopreserved human 
MSCs  or  (b)  human  MSCs  isolated  from  primary  un-
processed human marrow (both from Lonza, Walkersville, 
MD). From each condition, MSCs were expanded in a 
serum-containing growth medium (SCM) consisting of 
low-glucose  DMEM  supplemented  with  10%  MSC-
Qualified Fetal Bovine Serum (FBS), 2 mmol/L l-gluta-
mine,  and  5  µg/ml  gentamicin  (all  from  Invitrogen, 
Carlsbad,  CA)  to  passage  4,  where  equal  numbers  of 
MSCs from each donor were combined into a single MSC 
donor  pool  and  cryopreserved  at  1.0  ×  106  cells/ml 
(0.5 ml/vial) in complete SCM supplemented with 10% 
DMSO (Sigma-Aldrich, St. Louis, MO).
Human bone marrow-derived MSC recovery and expansion
To  recover  pooled  passage  4  human  MSCs,  each  vial 
(5 × 105 cells) was retrieved from liquid nitrogen and was 
quickly thawed and added to a 50-ml conical tube. To the 
recovered cell suspension, 10 ml of SCM was added by 
drops  (~5  drops/10  seconds  with  mixing)  and  placed 
directly  into  T225  culture  flasks  (BD  Biosciences, 
Franklin  Lakes,  NJ)  containing  30  ml  of  equilibrated 
SCM. Assuming ~90% cell recovery, the estimated post-
thaw seed density was ~2 × 103 cells/cm2. After 24 hours, 
complete  culture  medium  was  changed  to  remove 
residual DMSO and thereafter changed every 2 to 3 days 
until 70-90% confluence was attained. To test the ability 
of  serum-free  medium  (SFM;  StemPro®  MSC  SFM, 
Invitrogen) or SCM to support the expansion of human 
MSCs,  recovered  four-donor  pooled  human  MSCs 
(passage  5  total)  were  harvested  by  using  TrypLE™ 
Express (Invitrogen) and seeded at 3,000 cells/cm2 (SCM) 
or 10,000 cells/cm2 (SFM) in triplicate wells of six-well 
plates (BD Biosciences). Throughout the duration of the 
cultures,  individual  wells  remained  separate  and  were 
propagated  individually.  For  SFM  conditions,  culture 
vessels  were  coated  with  the  defined,  xenogeneic-free 
substrate CELLstart™ (1:100 dilution) or human plasma 
fibronectin  (5  µg/cm2)  (both  from  Invitrogen).  On 
reaching ~70-90% confluence, all human MSC cultures 
were harvested by using TrypLE™ Express (Invitrogen), 
counted by using a Coulter Counter (Beckman-Coulter, 
Fullerton, CA), and reseeded at the same seeding density 
through the duration of the study.
Primary human bone marrow-derived MSC isolation
Fresh unprocessed human bone marrow aspirate (Lonza) 
was obtained, and purified mononuclear cells were ob-
tained  by  using  a  Histopaque-1077  density  gradient 
(Sigma). To study the support of primary MSC expansion, 
2.0  ×  107  mononuclear  cells  were  seeded  into  a  T75 
culture flask coated with 5 µg/cm2 human plasma fibro-
nectin (Invitro  gen). After 3 days, complete medium was 
changed, and there  after, changed every 2 to 3 days. After 
8 days in culture, cells were harvested and propa  gated as 
described earlier.
Cell-proliferation assay
To optimize growth-factor requirements in SFM, cryo-
preserved four-donor pooled human MSCs recovered in 
SCM were harvested and seeded into 96-well black-wall 
tissue  culture-treated  plates  (Corning  Incorporated, 
Corning, NY) at 3,000 cells/cm2 in SCM or growth factor-
deficient SFM supplemented with various combinations 
of  the  recombinant  human  growth  factors  PDGF-BB, 
bFGF, and TGF-β1 (all from Invitrogen). After 4 days in 
culture,  cell  proliferation  was  measured  by  using  the 
CyQUANT® NF Cell Proliferation Assay (Invitrogen) by 
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(Molecular Devices, Sunnyvale, CA).
MSC differentiation and staining assays
Recovered passage 4 bone marrow MSCs from the four-
donor pool (passage 5 total) were expanded in SFM (eight 
passages;  passage  13  in  total)  and  seeded  into  StemPro® 
Osteogenesis,  Adipogenesis  or  Chondrogenesis  Differen-
tiation  medium  (Invitrogen)  in  12-well  plates  as  per  the 
manufacturers  protocol.  During  differentiation,  complete 
medium  changes  were  made  every  3  to  4  days.  After 
14  days,  cultures  were  monitored  for  differentiation  by 
using  lineage-specific  biologic  stains.  To  monitor  adipo-
genic differentiation, cultures were stained with Oil Red O 
(Sigma)  (0.5%  Oil  Red  O  solution  in  60%  isopropanol), 
washed with distilled water, and visualized. For chondro-
genic differentiation, micromass pellet cultures were fixed 
with  4%  formaldehyde  and  stained  with  1%  Alcian  Blue 
(Sigma).  After  staining,  cultures  were  washed  with  0.1N 
HCl  and  visualized.  For  osteogenesis,  staining  was  per-
formed by using the Leukocyte Alkaline Phos  phatase Kit 
(Sigma), as per the manufacturer’s protocol. In addition, to 
perform histologic staining on sectioned micromass pellet 
cultures,  single-donor  passage  1  bone  marrow  MSCs 
(isolated under standard SCM conditions) were propa  gated 
for  three  additional  passages  in  SCM  or  SFM  and  were 
resuspended at 1.25 × 106 cells/ml in chondrogenic medium 
composed  of  high-glucose  DMEM  (Invitrogen)  supple-
mented with 1% ITS+Premix (BD Biosciences), 100 µmol/L 
ascorbate-2-phosphate (WAKO, Richmond, VA), 10-7 mol/L 
dexa  metha  sone (Sigma), and 10 ng/ml TGFβ1 (Peprotech, 
Rocky Hill, NJ). To create chondro  genic micromass pellets, 
2.5 × 105 cells from this cell solution were placed in 96-well 
polypropylene plates (Phenix, Hayward, CA), centrifuged at 
500xg, and placed in an incubator at 37°C, 95% air, and 5% 
CO2. Medium changes were made 3 times per week, and on 
day 21 of differentiation, cell pellets were harvested, fixed 
with  10%  neutral-buffered  formalin,  paraffin-embedded, 
sectioned,  and  processed  for  histologic  evaluation  by 
staining with Toluidine blue.
Flow cytometry
Passage 3 human MSCs expanded in SCM or SFM were 
harvested  by  using  TrypLE™  Express  and  washed  with 
DPBS (without Ca2+/Mg2+) supplemented with 5% FBS and 
stained with the following antibodies: CD11b (un  conju-
gated,  clone  VIM12),  CD34-APC  (clone  581),  CD45-
AF405 (clone HI30), CD44-PE (clone MEM-85), CD105-
APC  (clone  SN6),  (all  from  Invitrogen);  CD90  (clone 
5E10), CD73-PE (clone AD2), (both from BD Biosciences); 
and  where  unconjugated  primary  anti  bodies  were  used, 
AlexaFluor®  488  anti-mouse  (Invitrogen).  To  set 
background fluorescence levels, unstained and/or matched 
isotype controls were used.
Colony-forming unit-fibroblast assay
MSC cultures (SFM and SCM) were harvested by using 
TrypLE™ Express, and the total cell number was deter-
mined by using a Coulter Counter. Harvested cells were 
reseeded  into  5  ×  100-mm  tissue  culture  dishes  (BD 
Biosciences)  at  150  cells/dish  (in  SCM  without  subse-
quent  medium  changes).  After  14  days,  cultures  were 
washed with DPBS and stained with 0.5% Crystal Violet 
(Sigma)  in  methanol  for  5  to  10  minutes  at  room 
temperature.  After  staining,  dishes  were  again  washed 
with DPBS, allowed to dry, and colonies (those greater 
than  50  cells)  were  counted  by  using  a  dissecting 
microscope. Data were reported as total colony number 
per  dish  (per  150  cells).  Standard  deviation  (SD)  was 
calculated.
RNA Isolation and qRT-PCR
To measure gene expression of selected surface antigens 
or other MSC markers, passage 4 human MSC cell pellets 
(single biologic replicate, triplicate technical replicates) 
were  collected,  and  RNA  was  isolated  by  using  the 
PureLink Micro-to-Midi Total RNA Purification Kit, and 
total RNA was DNase I-treated off-the-column, as per 
manufacturer’s protocol. To generate cDNA and run real-
time  quantitative  PCR  (qRT-PCR),  the  SuperScript  III 
Platinum SYBR Green Two-Step qRT-PCR Kit was used. 
qRT-PCR  analysis  was  completed  by  using  technical 
duplicates. The following primer sets were used:
CD73   -  F:CGCAACAATGGCACAATTAC,  
    R:CAGGTTTTCGGGAAAGATCA;
CD90   -  F:TCGCTCTCCTGCTAACAGTCT, 
    R:CTCGTACTGGATGGGTGAACT;
CD105   -  F:CACTAGCCAGGTCTCGAAGG,  
    R:CTGAGGACCAGAAGCACCTC;
NESTIN  -  F:ACCTCAAGATGTCCCTCAGC,  
    R:TGGGAGCAAAGATCCAAGAC 
(all reagents for RNA isolation and qRT-PCR were from 
Invitrogen).
Illumina microarray gene-expression analysis
Genome-wide  expression  profiles  of  human  bone 
marrow-derived  MSCs  grown  in  SFM  and  SCM  were 
obtained by using Illumina Bead Arrays. Total RNA was 
extracted using TRIzol and further purified of contami-
nating  genomic  DNA  by  using  DNA-free  (Ambion/
Applied Biosystems, Foster City, CA) for 30 minutes at 
37ºC.  RNA  was  precipitated  and  quantified  spectro-
photometrically,  and  its  purity  was  assessed  by  gel 
electro  phoresis.  Sample  amplification  and  biotinylated 
cRNA was prepared and generated from total RNA by 
using the Illumina total Prep kit (Ambion) according to 
the manufacturer’s protocol. Array hybridization to the 
Sentrix  Chip  Array  (Human  WG-6)  and  processing 
procedures  were  performed  according  to  protocols 
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Array  data  were  processed  and  analyzed  by  using 
Illumina BeadStudio software.
Results
The  developed  serum-free  supplement  consisted  of  a 
blend of essential amino acids, inorganic salts, and other 
components,  along  with  an  optimized  mix  of  the 
recombinant  human  growth  factors  PDGF-BB,  bFGF, 
and  TGF-β1.  This  blend  was  formulated  based  on  the 
effect of each individual growth factor or combination of 
factors on human MSC proliferation. Although supple-
mentation of certain individual factors or combinations 
of two factors provided enhanced expansion compared 
with a growth factor-deficient serum-free medium (SFM) 
or  10%  fetal  bovine  serum-containing  medium  (SCM) 
(Figure 1a), it was the combination of all three growth 
factors together that provided a robust synergistic effect 
on human MSC proliferation. It is noteworthy that along 
with  cell  proliferation,  a  drastic  change  in  cell  mor-
phology was observed in the presence of all three growth 
factors. Whereas growth factor-stimulated cells expanded 
in  SFM  displayed  a  small,  spindle-shaped  morphology, 
cells  grown  in  SCM  exhibited  a  more  flattened, 
characteristic fibroblast-like morphology (Figure 1b). In 
addition, cells continually propagated in SFM tended to 
grow in distinct bundles of cells, as compared with cells 
in SCM, which grew as a more-flattened, uniform mono-
layer of cells. To test the ability of the optimized SFM to 
support  continual  propagation  of  multipotent  MSCs, 
cryopreserved human bone marrow-derived MSCs from 
a  passage  4,  four-donor  pool  were  used  as  an  initial 
starting population. From this pool, cells were recovered 
in SCM and transitioned directly to SFM on CELLstart™ 
or  human  plasma  fibronectin-coated  vessels.  Cells 
cultured in SFM without the presence of a substrate on 
tissue  culture-treated  flasks  were  unable  to  achieve 
sufficient  initial  adherence  after  seeding  and  did  not 
proliferate in culture (data not shown). From this point, 
human MSCs were expanded in the SFM for eight con-
tinual  passages  (48  days;  passage  13  total)  (Figure  1c), 
after  which  cultures  slowed  and  were  therefore  termi-
nated. It is noteworthy that cells expanded in this SFM 
required a higher cell-seeding density (~1 × 104 cells/cm2) 
compared  with  that  historically  recommended  for 
traditional  SCM  cultures  [11].  As  cells  grown  in  SCM 
reached  confluence  at  a  lower  density,  the  resultant 
optimal passaging frequency of cells seeded at the same 
density  differed  between  SCM  and  SFM  cultures  and 
made a direct side-by-side comparison more difficult. To 
achieve  such  a  side-by-side  comparison,  cells  in  SCM 
were seeded at a lower seeding density (~3 × 103 cells/cm2), 
and net population doubling was used as a measure to 
compare the culture systems. To test the multipotentiality 
of  human  marrow-derived  MSCs  expanded  in  SFM,  a 
traditional trilineage mesoderm differentiation protocol 
was used. As shown in Figure 2a, human bone marrow-
derived MSCs grown for eight passages in SFM retained 
the ability to differentiate into adipocytes, chondrocytes, 
and osteoblasts, as shown by Oil Red O, Alcian blue, and 
alkaline phosphatase staining, respectively. In addition, 
human  bone  marrow-derived  MSCs  expanded  in  SFM 
from  a  single  donor,  passage  1  bank  revealed  robust 
chondrogenesis after three passages in SFM, as shown by 
dark  purple  staining  and  the  distinct  morphologic 
presence  of  chondrocytes  in  micromass  pellet  cultures 
(Figure  2b).  To  explore  the  ability  of  SFM  to  support 
primary  human  bone  marrow-derived  MSC  culture, 
fresh bone marrow mononuclear cells isolated by using a 
standard  density-gradient  centrifugation  protocol  were 
seeded into SFM and SCM. As shown in Figure 3b, after 
8 days, primary MSCs (passage 0) in SFM displayed a 
distinct spindle-shaped morphology. In addition, MSCs 
isolated under serum-free conditions showed continued 
expansion  potential  with  retained  trilineage  mesoderm 
differentiation potential (Figure 3a and b).
Historically, the colony-forming unit-fibroblast (CFU-F) 
assay  has  been  used  as  a  correlative  assay  to  test  the 
presence of clonal mesenchymal stem cells within a given 
cell  population  [2,12].  To  test  the  potential  of  cells 
expanded in SCM versus SFM, human MSCs passaged 
under each respective condition were placed into a CFU-
F assay. As shown in Figure 4, cells grown in SFM for two 
passages displayed a similar CFU-F potential compared 
with cells in SCM (11 ± 4 vs. 11 ± 5 (SD) respectively). In 
addition,  cells  continually  propagated  in  SFM  for  nine 
passages  displayed  a  similar  CFU-F  potential  to  that 
observed at passage 2.
To  test  further  the  phenotype  of  human  MSCs  ex-
panded in SFM, cell-surface antigens were analyzed by 
flow  cytometry  (passage  3)  (Table  1)  and  qRT-PCR 
(passage 4) (Table 2). Human MSCs expanded in SFM 
displayed a characteristic surface profile [13], including 
positive expression of CD73, CD90, and CD105, as well 
as  negative  expression  of  CD11b,  CD14,  CD19,  CD34, 
CD45,  and  CD79a.  Interestingly,  unlike  cells  grown  in 
SCM,  cells  expanded  in  SFM  displayed  a  significantly 
higher level of the type VI intermediate filament Nestin 
compared with cells expanded in SCM (Table 2).
To identify genotypic differences between cells expanded 
under  these  two  expansion-media  conditions,  a  global 
gene-expression  analysis  was  used.  Gene-expression 
analysis of MSC samples cultured in SCM or SFM was 
carried out by using the Illumina bead array containing 
46,000 full-length and splice-variant transcripts from the 
Human RefSeq database. Each transcript is represented 
by  a  50-mer  probe  present  on  an  average  of  30  beads 
within the BeadArray that provides high selectively and 
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Page 4 of 11Figure 1. Optimization of a serum-free growth medium. (a) Fluorescence-based quantification of human MSC proliferation in deficient serum-
free medium (SFM) supplemented with various combinations of recombinant human growth factors or in serum-containing medium (SCM) by 
using the CyQUANT NF Cell Proliferation Assay. D, growth factor-deficient SFM; P, SFM supplemented with recombinant human PDGF-BB; B, SFM 
supplemented with recombinant human bFGF; T, SFM supplemented with recombinant human TGF-β1. (b) Morphology of passage 4 human 
MSCs expanded in (a) SCM and (b) SFM. Magnification, 10× objective. (c) Recovered four-donor pooled human MSCs (passage 5) expanded under 
optimized conditions for eight additional passages (48 days) in SFM or SCM.
(a)
(b)
a b (c)
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Page 5 of 11reproducible results. The total number of genes detected 
over 0.99 confidence was considered for analysis. Samples 
were  clustered  to  plot  a  dendrogram  (Figure  5a). 
Dendrograms represent a form of hierarchical clustering, 
and are plotted with the raw global gene-expression data 
to determine the relatedness of samples. Clustering of the 
samples  represents  the  euclidean  distance,  with 
clustering together showing greater similarity than those 
far  from  each  other.  Cells  grown  in  SFM  for  varying 
passages clustered closer to each other than cells grown 
in SCM. Further pairwise comparison by using scatter-
plots  was  carried  out  to  determine  the  correlation 
between the global expression of cells grown for varying 
periods  in  SCM  and  SFM.  This  allows  estimation  of 
variability of the two samples based on the correlation 
coefficient (R2) value, with a value of closer to 1 indicating 
relatedness  and  a  value  farther  from  1  indicating 
Figure 2. Differentiation capacity of serum-free expanded human MSCs. (a) Day 14 differentiation cultures from cells expanded for eight 
additional passages in SFM revealed trilineage mesoderm differentiation, as shown by positive (a) Oil Red O staining for adipocytes, (b) Alcian blue 
staining for chondrocytes, and (c) alkaline phosphatase staining for osteoblasts. (a, c) 10×, (b) 20× objective. (b) Toluidine blue staining of day 21 
chondrogenic micromass-differentiation cultures after three passages in (a) serum-free medium or (b) serum-containing medium.
(a)
a b c
(b)
a b
Table 1. Flow-cytometric analysis of expanded human MSCs
 Flow cytometry  SFM  SCM
  target  % Positive (flow cytometry) 
    Negative human MSC markers
  CD11b  0.49  0.50
  CD34  0.26  1.04
  CD45  1.58  1.91
  CD79a  0.57  0.90
    Positive human MSC markers
  CD44  99.14  99.73
  CD73  99.38  99.90
  CD90  99.51  99.63
  CD105  97.95  99.78
Analysis of known positive and negative human MSC surface antigens by flow 
cytometry for cells expanded in both SFM and SCM for three passages.
Chase et al. Stem Cell Research & Therapy 2010, 1:8 
http://stemcellres.com/content/1/1/8
Page 6 of 11varia  bility. Figure 5b shows a pairwise comparison of the 
global gene-expression profile of human MSCs expanded 
in SFM versus SCM. Despite the clustering of SCM cells 
away from SFM in the dendrogram, the R2 value deter-
mined by scatterplot is 0.9188, and hence, they are not 
drastically different from each other. Further continual 
propagation  of  MSCs  in  SFM  medium  shows  minor 
changes  in  gene-expression  profiles,  and  the  extent  of 
this  change  is  similar  to  that  observed  with  MSCs 
continually  grown  in  traditional  SCM.  Further,  cells 
continually  propagated  in  either  formulation  for  an 
additional  four  passages  (Figure  5c  and  d)  show  close 
correlation with starting cultures, indicating that the cells 
do not have a significant deviation in gene expression as a 
result  of  continual  propagation  in  either  expansion 
medium. The complete gene-expression data are repre-
sented in Supplementary Table 1 in Additional file 1.
Discussion
To facilitate the transition of human MSC biology from 
basic  studies  to  clinical  application,  advances  in  the 
reagents  used  to  expand  these  therapeutically  relevant 
Figure 3. Primary isolation, culture expansion, and differentiation of human bone marrow-derived MSCs. (a) Net total cell expansion 
per flask for primary cultures grown in SFM for five continual passages. (b) (a) Morphology of passage 1 human bone marrow-derived MSCs in 
SFM. (b) Passage 5 MSCs in SFM were differentiated for 14 days and analyzed with (b) Oil Red O staining for adipocytes, (c) Alcian blue staining for 
chondrocytes, and (d) alkaline phosphatase staining for osteoblasts. a-d, 10× objective.
(a)
(b)
a d c b
Table 2. Quantitative real-time PCR analysis of expanded human MSCs
  qRT-PCR  SFM  SCM
  target  Expression  ΔCt  Expression level  ΔCt
      Positive Human MSC markers
  CD44  N/A  N/A  N/A  N/A
  CD73  ++++  2.55  ++++  3.53
  CD90  ++++  2.40  ++++  2.63
  CD105  ++++  2.63  ++++  1.82
  Nestin  +++  5.79  ++  11.17
Quantitative real-time PCR analysis of known positive human MSC surface antigens for cells expanded in both SFM and SCM after four passages. ΔCt, Ct (gene-of-
interest) - Ct (GAPDH), ++++, very high; +++, high; ++, moderate; +, low.
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important achievements in this area will be the transition 
from  SCM  to  a  better-defined  SFM.  Although  recent 
efforts  have  shown  that  human  placenta  and  bone 
marrow-derived  MSCs  can  be  isolated  and  expanded 
over  the  short  term  in  serum-free  medium  [14],  no 
published work had shown the ability to expand human 
MSCs under serum-free conditions for the long term in 
culture. To achieve such a feat, the optimized serum-free 
medium StemPro® MSC SFM was developed [10]. Perhaps 
one  of  the  most  important  features  of  this  serum-free 
formulation was the optimization of the growth factors 
required  for  optimal  human  MSC  expansion.  Three  of 
the most important growth factors described as playing a 
role in both human MSC proliferation and differentiation 
are PDGF-BB, bFGF, and TGF-β1 [10]. Whereas PDGF-BB 
and bFGF had positive effects on cell growth individually, 
TGF-β1  appeared  to  provide  no  enhancement  of  cell 
proliferation on its own. Interestingly, although combina-
tions  of  any  two  growth  factors  appeared  to  provide 
minimal or no significant enhancement of cell prolifera-
tion compared with single factors, the combination of all 
three factors provided an obvious synergistic effect.
To test the ability of the optimized SFM to support 
continual  propagation,  established  MSC  cultures  in 
SCM  were  transitioned  directly  into  SFM.  It  is 
important to note the difference in morphology of cells 
in  SFM  versus  SCM.  On  removing  from  serum,  cells 
grown  in  SFM  adopted  a  more  spindle-shaped 
morphology  with  a  distinct  cell-growth  pattern.  This 
morphology allowed cells in SFM to be grown at much 
higher densities compared with cells grown in SCM. As 
a result, this morphologic change caused cells cultured 
in SCM versus SFM to require different seeding den-
sities or passage frequencies or both. Also, unlike cells 
grown in SCM, which can be grown optimally at very 
low seeding densities, cells in SFM appeared to perform 
better at higher seeding densities (~1 × 104 cells/cm2), 
facilitating  optimal  cell  expansion  and  continual 
propagation. The ability to expand human MSCs at high 
densities  with  retained  multipotency  provides  a 
beneficial approach.
As the MSC field moves toward the establishment of 
more-robust and efficient clinical protocols, the ability to 
expand large numbers of cells at high density quickly by 
using fewer culture wares and reagents may prove very 
useful.  It  is  noteworthy  that  cells  transitioned  directly 
from SCM to SFM may have shown enhanced prolifera-
tion for the first one to two passages directly out of SCM. 
After  two  passages,  SFM  cultures  provided  an  average 
expansion rate (doubling time; average for eight passages) 
similar  to  that  achieved  with  SCM  (46.3  ±  7.1  versus 
52.5 ± 6.9 (SD) hours, respectively). In addition, similar 
to that described recently [15], our optimized SFM was 
capable of supporting expansion of MSCs directly from 
primary  human  bone  marrow.  Unlike  typical  observa-
tions for primary cultures in SCM, those in SFM did not 
result in fibroblast colonies, but rather generated some-
what  evenly  distributed  proliferative  MSC-like  cells 
through  out the culture flask. The reason for this different 
growth pattern is unknown, but may be a result of the 
substrate  (human  plasma  fibronectin  or  CELLstart™) 
required  for  MSC  growth  in  SFM  or  the  presence  of 
recom  binant  human  growth  factors  (PDGF-BB,  bFGF, 
Figure 4. CFU-F assay of serum-free expanded human MSCs. (a) Representative images of 14-day CFU-F colonies initiated from (a) passage 2 
SFM cultures (passage 7 total), (b) passage 2 SCM cultures (passage 7 total), and (c) passage 9 SFM cultures (passage 14 total). (b) Enumeration of 
CFU-F colonies (those ≥50 cells) at each respective passage. Data shown represent n = 5 technical replicates.
(b)
a b c
(a)
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Page 8 of 11and  TGF-β1),  which  have  been  described  as  having  a 
migratory effect on MSCs [16-19].
It is important to note that the described multipassage 
expansion  experiments  were  conducted  by  using  (a) 
pooled  passage  4  human  MSCs  isolated  in  SCM  from 
four  individual  donors  and  transitioned  to  SFM;  (b) 
single-donor  human  MSCs  isolated  in  SCM  and 
transitioned  to  SFM;  and  (c)  primary  human  MSCs 
isolated directly in SFM from a single donor. Although 
the  presented  data  do  not  directly  address  donor-to-
donor  variability  and  the  efficacy  for  human  MSCs 
isolated in SCM versus SFM, it is noteworthy that Agata 
et  al.  [15]  directly  addressed  these  questions.  In  this 
work, the authors concluded that the efficacy of primary 
Figure 5. Transcriptome comparison of MSCs cultured in serum-free and serum-containing media. (a) Dendrogram showing the relatedness 
of cells based on global gene expression obtained by using Illumina bead array and analyzed by using Bead Studio. (b-d) Pairwise comparison of 
global gene-expression profiles of MSCs maintained in SCM and SFM. Data points >0.99 detection limit are represented in red. Points lying outside 
the green line represent genes with greater than twofold difference, whereas R2 values closer to 1 suggest similarity in global gene expression. 
(b) Human MSCs in SCM and SFM after passage 2 (P2). (c) Comparison of cells grown for two passages (P2) versus cells grown for six passages (P6) 
in SCM. (d) Comparison of cells grown for two passages (P2) versus cells grown for six passages (P6) in SFM.
(a)
(b)
(c) (d)
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that this effect was independent of specific donors.
The  use  of  pooled  human  MSCs  in  our  study  was 
intended  to  overcome  donor-to-donor  variability  and 
provide a reliable and consistent population of MSCs for 
experimentation.  Although  this  approach  certainly 
provides  a  consistent  average  population  of  cells  for 
relatively short-term cultures, it is possible during long-
term culture that human MSCs from a single donor (or 
donors)  with  faster  growth  rates  may  overtake  the 
cultures and therefore provide a less-average and more-
optimal result.
Despite the nontraditional growth patterns, morpho-
logy,  and  expansion  protocols  required  for  growing 
human MSCs in SFM, expanded MSCs in this medium 
still displayed multipotentiality with successful differen-
tiation to adipocytes, osteoblasts, and chondrocytes. As 
the chondrogenic potential of cultured MSCs is often the 
first differentiation capacity lost during in vitro expansion 
(unpublished  results),  the  apparent  retained  robust 
chondrogenic  differentiation  potential  shown  through 
pellet cultures and Toludine Blue O staining is a promis-
ing characteristic provided by this serum-free medium. 
As described by Agata et al. [15], human bone marrow-
derived  MSCs  isolated  and  expanded  in  SFM  still 
retained  the  competence  for  osteogenic  induction  and 
ectopic bone formation.
As proposed previously by the International Society for 
Cell  Therapy  [13],  a  population  of  multipotent  human 
MSCs  must  possess  a  specific  cell-surface  antigen 
expression  profile.  In  accordance  with  that  defined  by 
this group, cells grown in SFM displayed positive expres-
sion of CD73, CD90, and CD105 and negative expression 
of  CD11b,  CD14,  CD19,  CD34,  CD45,  and  CD79a,  as 
detected  by  quantitative  real-time  PCR  and  flow 
cytometry.  Interestingly,  cells  grown  in  SFM  displayed 
significantly  enhanced  expression  of  the  intermediate 
filament nestin. Whereas nestin was originally identified 
as a marker for neural stem cells [20], it has since been 
reported to be present in numerous cell types including 
human MSCs [21]. As pericytes have been suggested the 
in vivo origin of in vitro expanded human MSCs [22,23] 
and have been reported to express nestin in vivo [24,25], 
it  may  be  possible  that  nestin  expression  represents  a 
more in vivo phenotype for expanded MSCs.
After an analysis of gene-expression data generated on 
SFM  versus  SCM  cultures,  dendrogram  results  reveal 
that, over multiple passages, cells grown in SFM clustered 
together and cells in SCM cluster together. Despite this 
clustering, the pairwise comparison of SFM versus SFM 
global gene expression (passage 2; R2 = 0.9188) suggests a 
close  correlation  between  the  expression  pattern  of 
MSCs grown in SCM and SFM. In addition, cells grown 
in  either  medium  for  additional  passages  continue  to 
show close correlation with earlier passaged cells in the 
same  medium,  suggesting  minimal  genotypic  changes. 
Although differences in gene-expression analysis between 
MSCs grown in SFM and SCM do not seem to have an 
impact on either proliferation or multipotency, a more-
detailed  analysis  on  the  effect  these  differentially 
expressed genes may play on overall MSC biology must 
be further explored. It is important to note that the bulk 
of the characterization data provided in this work was 
conducted on cells isolated by using SCM and thereafter 
transitioned to SFM and further expanded under such 
conditions.  As  the  possibility  exists  that  the  standard 
SCM isolation procedure may result in the selection of a 
certain population of primary cells (MSCs) with a distinct 
phenotype, it cannot be ruled out that such characteri-
zation experiments (that is, gene-array studies) may differ 
when comparing cells isolated under SCM versus SFM 
conditions.
In addition to the data presented here focusing on the 
expansion of human bone marrow-derived MSCs, it has 
also been observed that the described SFM may be used 
for  expansion  of  human  MSCs  from  other  sources 
including  umbilical  cord-derived  MSCs  and  adipose-
derived  stem  cells  (ADSCs)  (unpublished  data).  Despite 
the preliminary data suggesting the ability to expand these 
additional MSC populations in SFM, future studies will be 
necessary to determine whether additional supplemen  tation 
is necessary most efficiently to expand these populations.
Conclusions
The development of a serum-free medium for the isolation 
and expansion of human MSCs represents a necessary 
step  in  developing  the  tools  required  to  study  human 
MSCs  in  a  consistent  and  reproducible  manner.  By 
eliminating the use of fetal bovine serum, an inherently 
variable  reagent,  this  novel  serum-free  medium  will 
provide  the  ability  for  researchers  from  different 
laboratories  to  conduct  studies  with  similar  reagents, 
fostering scientific advances and discovery. Future studies 
will  be  necessary  to  realize  completely  the  effect  this 
medium  has  on  MSC  biology  in  vivo.  Finally,  as  this 
described  SFM  contains  nonhuman  animal-origin 
materials, future optimization and medium development 
leading to a serum-free, xenogeneic-free and therefore a 
more clinically relevant culture system will be necessary.
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